PowerPoint Slide Style Guide

Size: px
Start display at page:

Download "PowerPoint Slide Style Guide"

Transcription

1 PowerPoint Slide Style Guide

2 Introduction and overview This style guide aims to help you design Abbott speaker slide decks that have a uniform and consistent look both within the deck itself and among multiple decks we create for our client. This guide presumes you have a working knowledge of PowerPoint and are familiar with PowerPoint templates. This style guide is designed to show you how to use our pre-designed templates to create slides for the majority of layout situations you will encounter. For the writer, the various font sizes and colors are already built in to the template, so you should be able to just start typing. Using the templates will insure that all slides have a consistent visual look regarding background image, style and color of text and placement of images. This should also make deck creation easier and more efficient. This Style guide will evolve and be updated as we learn together the best way to build great PowerPoint decks for our client! 2

3 Important Do s and Don ts Do s: Please use the template to build your slide from scratch rather than creating the content in a Word document first. Doing so will allow you to see the look of your slide immediately, and help you appreciate total content per slide (and indicate when it s time to start a new slide!). Look through this guide before you start, to identify the various templates at your disposal, and pick the right template on which to build your slide. Remember to keep in mind that when insertions are used (pictures, charts, video.), you will need to involve your art director to insure that they meet HUMIRA branding guidelines and are of sufficient resolution and quality. Don t: Please try not to move any of the objects on the slide, such as the positioning of text or art boxes. Your Art Director will provide a final consistency styling check at key intervals (and especially as the project nears completion), but will be greatly aided by your preservation of template settings. Try not to make any changes to the template. If something is not fitting/working, work with your Art Director to find a solution. Don t add or remove branding elements ( Abbott or HUMIRA ) if a given slide needs to be altered (eg, per MLR direction), have, an Art Director make this change. 3

4 Table of Contents Background templates... 5 Title slide... 6 Title with description text... 7 Slide picture on left... 8 Slide picture-middle... 9 Text without bullets ISI slide Slide with chart Slide with table Master view thumbnails Chart and table font styles defined Note pages defined Global Specifications... 22

5 Background templates These are the ONLY authorized background templates. Using them on all branded and unbranded slide decks will result in a consistent visual presentation. Branded template Ankylosing Spondylitis Background Abbott Sponsorship DisclosureAbbott Sponsorship Disclosure In 1997, adalimumab, the first fully human monoclonal antibody targeted against TNF, was first administered to a study patient HUMIRA is a recombinant human IgG1 monoclonal antibody specific for This program is sponsored by, and on behalf of, Abbott, and the This program is sponsored by, and on behalf of, Abbott, and the human TNF. HUMIRA was created using phage display technology presentation contents are consistent resulting with an antibody with human-derived heavy and presentation light chain contents are consistent with all applicable FDA variable Ankylosing all applicable FDA regions and human IgG1:k constant regions Spondylitis requirements. The Speaker for this program has been selected by requirements. The Speaker for this program has been selected by Abbott This report represents Sponsorship a safety analysis of adalimumab Disclosure across six Abbott Sponsorship Disclosure Abbott and is presenting the program material on Abbott s behalf. Abbott and is presenting the program material on Abbott s behalf. This immune-mediated program is sponsored inflammatory by, diseases and on behalf of, Abbott, and the This program is sponsored by, and on behalf of, Abbott, and the presentation contents are consistent with all applicable FDA presentation contents are consistent with all applicable FDA Authors evaluated safety data from approximately 10 years of requirements. adalimumab clinical The Speaker trial experience for this program has been selected by requirements. The Speaker for this program has been selected by Abbott and is presenting the program material on Abbott s behalf. Abbott and is presenting the program material on Abbott s behalf. Ankylosing Spondylitis Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68: Please see Important Safety Information, including BOXED WARNING on Serious Infections and Malignancy, on slides 5-8. Title slide Interior slides with logo 3 Interior slides without logo 3 Unbranded templates AbbottSponsorshipDisclosure This Program is sponsored by, and on behalf of, Abbott. The presentation contents are consistent with all applicable FDA requirements, including FDA-approved product labeling. The Speaker for this Program has been selected by Abbott and is presenting the Program material on Abbott s behalf. Title slide Interior slides 2 5

6 Title slide Safety Area 7.65 inch x 6.7 inch.5 2 Ankylosing Spondylitis Center vertically Flush left to safety 1 Text; Arial 36 points, Black Leading 38 Flush Left Use this Slide Master PowerPoint Fonts 6

7 Slide with descriptive text.5 Important Safety Considerations (cont.) 2 SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested Abbott Sponsorship Disclosure negative for latent TB infection prior to initiating therapy. MALIGNANCY This program is sponsored by, and on behalf of, Abbott, and the presentation contents are consistent with all applicable FDA requirements. The Speaker for this program has been selected by Abbott and is presenting the program material on Abbott s behalf. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member. Malignancies Seen more often than in controls. Lymphoma, non-melanoma skin cancer, acute and chronic leukemia, and others have been reported. Hypersensitivity Anaphylaxis or serious allergic reactions may occur. Stop HUMIRA and begin appropriate therapy. Center vertically Flush left to safety Points. RGB-214,0,87 Flush left, exact leading 18 Points Arial italic Black, Flush left exact leading 20 points Use this Slide Master PowerPoint Fonts 7

8 Slide -picture on left Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 2 Ankylosing Spondylitis (AS) Chronic inflammatory disease Saxial skeleton Peripheral joints All images Sites affected Entheses and text Clinical signs/symptoms Chronic inflammatory back pain Sacroiliitis Impaired spinal mobility Reduction of chest expansion Enthesitis Radiographic hallmark: sacroiliitis Absence of rheumatoid factor Association with HLA-B27 Bullets: 115% size RGB-214,0,87 Text; Arial 18 points, Black, Sub-bullets 16 points, Bullets and sub-bullets require consistent spacing leading 16 points space after 6 points Leading between sub-bullets 16 points no space after or before van der Heijde D. In: Klippel JH et al, eds. Primer on the Rheumatic Diseases. 13th ed. 2008; van der Linden S et al. In: Firestein GS et al, eds. Kelley s Textbook of Rheumatology, 8 th ed. Text 100% Black 8 points/10 points Code: Arial 8 pts,white, aligns with page number bottom 4 Page Number: 100% Black 8 points. centered on yellow bar 12 points Space after Picture Flush left Use maximum height Size with white space align with Text Use this Slide Master PowerPoint Fonts 8

9 Slide -picture in middle 2 Sacroiliitis Synovitis/enthesitis Cartilage destruction/bone erosions New bone formation Bony ankylosis Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 All images and text Sacroiliac joints in an AS patient Bullets: 115% size RGB=214,0,87 Text; Arial 16 points, Black Indentation 0.2 Hanging 0.2 Spacing Before 12 points After 6 points Exact leading 16 points Text box Layout vertical alignment Top Text and graphic content vertically centered within safety area van der Heijde D. In: Klippel JH et al, eds. Primer on the Rheumatic Diseases. 13th ed. 2008; Francois RJ et al. Arthritis Rheum. 2000;43: Text 100% Black 8 points./10 points Code: Arial 8 pts,white, aligns with page number bottom Page Number: 100% Black 8 points. centered on yellow bar Image Flush left use width of safety for sizing Picture Flush left use maximum width. Size with white space Use this Slide Master PowerPoint Fonts 9

10 Slide -text without bullets Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 AS and RA Indications HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 2 HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. 6 Text 100% Black 8 points./10 points. Text box vertical alignment Bottom Code: Arial 8 pts,white, aligns with page number bottom Page Number: 100% Black 8 points. centered on yellow bar Arial Bold & Regular 18 points. no indent 6 points. before 6 points after single space leading Text box Layout vertical alignment Top Use this Slide Master PowerPoint Fonts 10

11 Slide -ISI Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 Important Safety Considerations WARNINGS SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were SERIOUS INFECTIONS (continued) Important Safety Considerations (cont.) taking concomitant immunosuppressants such as methotrexate or corticosteroids. HUMIRA The risks and should benefits be of treatment discontinued with HUMIRA if a patient should develops be carefully a serious considered infection prior to or sepsis. Reported initiating therapy infections patients include: with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, Active tuberculosis including the possible (TB), including development reactivation of TB in patients of latent who TB. tested Patients with TB have negative for latent frequently TB infection presented prior to initiating with disseminated therapy. or extrapulmonary disease. Patients should be tested for latent TB before HUMIRA use and during therapy. Treatment for latent infection MALIGNANCY should be initiated prior to HUMIRA use. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients Invasive treated fungal with infections, TNF blockers, including of which histoplasmosis, HUMIRA a member. coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other Malignancies invasive Seen more fungal often infections than controls. may present Lymphoma, with disseminated, non-melanoma rather skin than localized, disease. cancer, acute Antigen and chronic and leukemia, antibody and testing others for have histoplasmosis been reported. may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for Hypersensitivity invasive Anaphylaxis fungal infections or serious who allergic develop reactions severe may systemic occur. illness. Stop HUMIRA and begin appropriate therapy. Bacterial, viral and other infections due to opportunistic pathogens. 6 7 Text 100% Black 8 points/10 points. Code: Arial 8 pts,white, aligns with page number bottom Page Number: 100% Black 8 points. Centered on yellow bar Arial Bold 12 points, Flush left, edge of safety area Arial Bold 12 points. no indent 6 points. before 6 points after single space leading Text box Layout vertical alignment Top text inset 0.2 equal sides 1 pt Black rule Bullets :RGB=214, 0, 87 Use this Slide Master PowerPoint Fonts 11

12 1. Slide -ISI continued Important Safety Considerations (cont.) ISI slides are already formatted. Just copy and paste into your new presentation. 2 Important Safety Considerations (cont SERIOUS INFECTIONS (continued) SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to The risks and benefits of treatment with HUMIRA should be carefully consi initiating therapy in patients with chronic or recurrent infection. Patients should be closely initiating therapy in patients with chronic or recurrent infection. Patients s monitored for the development of signs and symptoms of infection during 2. and after monitored for the development of signs and symptoms Important Safety Considerations (cont d) 1 of infection during Important treatment with Safety HUMIRA, Considerations including the possible 1 development of TB in patients who tested treatment with HUMIRA, including the possible development of TB in patie negative 1.4 for latent TB infection prior to initiating therapy. negative 1.4 for latent TB infection prior to initiating therapy. WARNINGS 2 SERIOUS INFECTIONS (continued) MALIGNANCY SERIOUS INFECTIONS The MALIGNANCY risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely Lymphoma Patients treated with and HUMIRA other are at malignancies, increased risk for developing some serious fatal, infections have been that reported in children monitored Lymphoma for the development and other of signs malignancies, and symptoms of some infection fatal, during and have after been reported in child may lead to hospitalization or death. Most patients who developed these infections were and treatment with HUMIRA, including the possible development of TB in patients who tested taking adolescent concomitant immunosuppressants patients treated such as with methotrexate TNF or blockers, corticosteroids. of HUMIRA which HUMIRA is a member. and adolescent patients treated with TNF blockers, of which HUMIRA is a m negative for latent TB infection prior to initiating therapy. should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: MALIGNANCY Malignancies Active tuberculosis (TB), including Seen reactivation more often latent TB. than Patients in with controls. TB have Lymphoma, non-melanoma skin Lymphoma Malignancies and other malignancies, Seen some more fatal, have often been reported than in children controls. Lymphoma, noncancer, acute and chronic leukemia, and others have been reported frequently presented with disseminated or extrapulmonary disease. Patients should be and adolescent patients treated with TNF blockers, of which HUMIRA is a member. cancer, tested for latent acute TB before and HUMIRA chronic use and leukemia, during therapy. Treatment and others for latent infection have been reported. should be initiated prior to HUMIRA use. Malignancies Seen more often than in controls. Lymphoma, non-melanoma skin Hypersensitivity Invasive fungal infections, including Anaphylaxis histoplasmosis, coccidioidomycosis, or serious allergic candidiasis, reactions may occur. cancer, Hypersensitivity acute and chronic leukemia, Anaphylaxis and others have or been serious reported. allergic reactions may oc aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other Stop invasive HUMIRA fungal infections and may present begin with appropriate disseminated, rather therapy. than localized, disease. Hypersensitivity Stop HUMIRA Anaphylaxis and begin or serious appropriate allergic reactions therapy. may occur. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens. Stop HUMIRA and begin appropriate therapy. 17 Please see Abbott Representative Important for Safety full Prescribing Information. Considerations (cont.) 7 18 Important Please see Abbott Representative Safety for Considerations full Prescribing Information. (cont 7 ISI layouts SERIOUS INFECTIONS (continued) SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating The risks therapy and benefits in patients of treatment with chronic with HUMIRA or recurrent should infection. be carefully Patients considered should be prior closely to monitored initiating therapy for the in development patients with of chronic signs and or recurrent symptoms infection. of infection Patients during should and after be closely monitored for the development of signs and symptoms of infection during treatment monitored with for the HUMIRA, development including of signs the possible and symptoms Important Safety Considerations (cont d) development 1 of infection of TB in during patients and who after tested Important treatment with Safety HUMIRA, Considerations including the possible (cont d) development negative treatment for with latent HUMIRA, TB infection including prior the to possible initiating development therapy. of TB in patients who tested 1 of TB in patien negative negative for latent TB infection prior to initiating therapy. 1.4 for latent TB infection prior to initiating therapy. Anakinra Increased risk of serious infections. Combination of Hepatitis B reactivation Increased risk of reactivation in patients who MALIGNANCY HUMIRA and anakinra is not recommended. MALIGNANCY MALIGNANCY are chronic carriers. Some cases have been fatal. If reactivation occurs, Lymphoma Live vaccines and Should other not malignancies, be given to patients some on HUMIRA. fatal, have been reported in children Lymphoma stop HUMIRA and begin other anti-viral malignancies, therapy. some fatal, have been reported in child and Lymphoma adolescent and patients other malignancies, treated with some TNF blockers, fatal, have of been which reported HUMIRA in is children member. and adolescent patients treated with TNF blockers, of which HUMIRA is a member. and Demyelinating adolescent disease patients Exacerbation treated with or new TNF onset blockers, may occur. of which HUMIRA is a m Exercise caution when considering HUMIRA for patients with these disorders. Malignancies Seen more often than in controls. Lymphoma, non-melanoma skin Malignancies Seen more often than in controls. Lymphoma, non-melanoma skin Malignancies Seen more often than in controls. Lymphoma, non-m cancer, acute and chronic leukemia, and others have been reported. Hematological reactions Cytopenias, pancytopenia. Advise patients to cancer, acute and chronic leukemia, and others have been reported. cancer, acute and chronic leukemia, and others have been reported seek immediate medical attention if symptoms develop, and consider stopping HUMIRA. Hypersensitivity Anaphylaxis or serious allergic reactions may occur. Hypersensitivity Anaphylaxis or serious allergic reactions may occur. Hypersensitivity Anaphylaxis or serious allergic reactions may oc Stop HUMIRA and begin appropriate therapy. Heart failure Worsening or new onset CHF may occur. Exercise Stop HUMIRA and begin appropriate therapy. caution Stop HUMIRA when using HUMIRA and begin in patients appropriate who have heart therapy. failure and Discontinuations due to adverse events were 7% for HUMIRA vs monitor them carefully. 4% for placebo In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn s disease, and plaque psoriasis the safety profile for patients treated with HUMIRA was similar to the safety profile seen in patients with rheumatoid arthritis SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully consi initiating therapy in patients with chronic or recurrent infection. Patients sh Autoimmunity Development of autoantibodies and lupus-like syndrome. Stop HUMIRA if lupus-like syndrome

13 Slide with chart Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 PREMIER 2-Year Study Design Early Moderate to Severe RA.5 2 All images and text Chart placed as jpg from Illustrator File with Text to unify font a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and corticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, as needed/as tolerated. Breedveld FC et al. Arthritis Rheum. 2006;54: Text 100% Black 8 points/10 points Hanging 0.2 Spacing Before 0 points After 6 points Leading Exact 10 points Text box vertical alignment Bottom Page Number: 100% Black 8 points. Centered on yellow bar Code: Arial 8 pts,white, aligns with page number bottom Use this Slide Master PowerPoint Fonts Charts Fonts 47 Light Condensed 57 Condensed 77 Bold Condensed 97 Black Condensed 13

14 Slide with chart Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 2 PREMIER: Mean Change From Baseline in mtss 2 SERIOUS INFECTIONS (continued) All images The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of and text infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member..5 Chart placed as jpg from Illustrator File with Text to unify font size to maxium width a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and c orticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, asneeded/as tolerated. Breedveld FC et al. Arthritis Rheum. 2006;54: Text 100% Black 8 points/10 points Hanging 0.2 Space Before 0 points, Space After 6 Page Number: 100% Black 8 points. Centered on yellow bar Code: Arial 8 pts,white, aligns with page number bottom Use this Slide Master PowerPoint Fonts Charts Fonts 47 Light Condensed 57 Condensed 77 Bold Condensed 97 Black Condensed 14

15 Slide with chart Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 ACR50/70 Response Rates at Years 1 and 2 ACR50/70 Response Rates at Years 1 and All images and text Chart placed as jpg from Illustrator File with Text to unify font a Analysis is of the intent-to-treat (ITT) study population using nonresponder imputation (NRI) a Breedveld FC et al. Arthritis Rheum. 2006;54:26-37 Analysis is of the intent-to-treat (ITT) study population using nonresponder imputation (NRI) Breedveld FC et al. Arthritis Rheum. 2006;54:26-37 Please see Important Safety Information, including BOXED WARNING on Serious Infections and Malignancy, beginning on slide 40. Please see Important Safety Information, including BOXED WARNING 12 on Serious Infections and Malignancy, beginning on slide Text 100% Black 8 points/10 points Hanging 0.2 Code: Arial 8 pts,white, aligns with page number bottom Page Number: 100% Black 8 points centered on yellow bar Arial Bold Flush left, 12 points Use this Slide Master PowerPoint Fonts Charts Fonts 47 Light Condensed 57 Condensed 77 Bold Condensed 97 Black Condensed 15

16 Slide with table Headline starts at edge of safety area text box vertical alignment must be set to top Arial Bold=24 points single line leading RGB=214, 0, 87 Baseline Characteristics *.5 Baseline Characteristics * 2 All images and text Table placed as jpg from Illustrator File with Text to unify font size to maximum width Unless otherwise indicated, results are mean ± SD. a n=267 Unless in otherwise HUMIRA indicated, + MTX results group, are 271 mean in the ± SD. HUMIRA monotherapy group, and 251 in the MTX a n=267 Breedveld in the FC HUMIRA et al. Arthritis + MTX Rheum. group, 2006;54: in the HUMIRA monotherapy group, and 251 in the MTX 11 Breedveld FC et al. Arthritis Rheum. 2006;54: Text 100% Black 8 points/10 points Code: Arial 8 pts,white, aligns with page number bottom Page Number: 100% Black 8 points. centered on yellow bar Use this Slide Master PowerPoint Fonts Table Fonts: 57 Condensed 77 Bold Condensed 97 Black Condensed 16

17 Thumbnail Specific master view slide of Master layouts Slide Layout names Title all caps Title with italic text Headline with text Case Study A 30-year-old white male construction worker referred by orthopedist for evaluation of low back pain and abnormal spine imaging studies Ankylosing Spondylitis Abbott Sponsorship Disclosure This Program is sponsored by, and on behalf of, Abbott. The presentation contents are consistent with all applicable FDA requirements, including FDAapproved product labeling. The Speaker for this program has been selected by Abbott and is presenting the Program material on Abbott s behalf. History: Five-year history of on-and-off low back pain. Pain is prominent in the morning and associated with stiffness. OTC NSAIDs have been somewhat helpful, but now the pain is becoming more frequent and persistent. X-rays showed bilateral sacroiliitis Other ROS reveals enthesitis of Achilles tendon What other diagnostic test(s) would you order? 2 3 Headline with bullets and picture Head with picture Headline with text Ankylosing Spondylitis (AS) Chronic inflammatory disease Saxial skeleton Peripheral joints Sites affected Entheses Clinical signs/symptoms Chronic inflammatory back pain Sacroiliitis Impaired spinal mobility Reduction of chest expansion Enthesitis Sacroiliitis Synovitis/enthesitis Cartilage destruction/bone erosions New bone formation Bony ankylosis Sacroiliac joints in an AS patient AS and RA Indications HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Radiographic hallmark: sacroiliitis Absence of rheumatoid factor Association with HLA-B27 van der Heijde D. In: Klippel JH et al, eds. Primer on the Rheumatic Diseases. 13th ed. 2008; van der Linden S et al. In: Firestein GS et al, eds. Kelley s Textbook of Rheumatology, 8 th ed. van der Heijde D. In: Klippel JH et al, eds. Primer on the Rheumatic Diseases. 13th ed. 2008; van der Linden S et al. In: Firestein GS et al, eds. Kelley s Textbook of Rheumatology, 8 th ed ISI 1 Head with chart Headline with chart Important Safety Considerations 1 PREMIER 2-Year Study Design Early Moderate to Severe RA Disease Course WARNINGS SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. HUMIRA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before HUMIRA use and during therapy. Treatment for latent infection should be initiated prior to HUMIRA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens. Image reproduced with permission from the American College of Rheumatology. AS does not follow a single defined course Highly variable, characterized by spontaneous remission and exacerbation Disease may remain active for decades Predictive factors for severe disease include early hip involvement a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and corticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, as needed/as tolerated. Breedveld FC et al. Arthritis Rheum. 2006;54: van der Linden S et al. In: Firestein GS et al, eds. Kelley s Textbook of Rheumatology, 8th ed. 2008;

18 Specific Master Slide Layouts (continued) Headline with chart Headline with chart Headline with chart PREMIER 2-Year Study Design Early Moderate to Severe RA SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member. Baseline Characteristics * ACR50/70 Response Rates at Years 1 and 2 Unless otherwise indicated, results are mean ± SD. a n=267 in the HUMIRA + MTX group, 271 in the HUMIRA monotherapy group, and 251 in the MTX a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and c orticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, asneeded/as tolerated. Breedveld FC et al. Arthritis Rheum. 2006;54: Breedveld FC et al. Arthritis Rheum. 2006;54: a Analysis is of the intent-to-treat (ITT) study population using nonresponder imputation (NRI) Breedveld FC et al. Arthritis Rheum. 2006;54:26-37 Please see Important Safety Information, including BOXED WARNING on Serious Infections and Malignancy, beginning on slide Title centered no logo Headline with text ISI 1 indent HUMIRA (adalimumab): ATLAS (the Adalimumab Trial Evaluating Long-term Efficacy and Safety in AS) Conclusions ATLAS More patients treated with HUMIRA achieved ASAS20 (the primary endpoint) compared to placebo patients at week 12 (58% vs 21%) HUMIRA showed statistically significant difference compared to placebo in ASAS50, ASAS70, BASDAI, BASFI, BASMI, CRP, and MASES Patients treated with HUMIRA had significant improvements in SF-36 PCS and ASQOL scores In HUMIRA clinical trials for ankylosing spondylitis, the safety profile for patients treated with HUMIRA was similar to the safety profile seen in patients with rheumatoid arthritis Important Safety Considerations (cont d) 1 SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member. Malignancies Seen more often than in controls. Lymphoma, non-melanoma skin cancer, acute and chronic leukemia, and others have been reported. Hypersensitivity Anaphylaxis or serious allergic reactions may occur. Stop HUMIRA and begin appropriate therapy ISI 2 box and text ISI with chart Important Safety Considerations (cont d) Important Safety Considerations (cont d) 1 Hepatitis B reactivation Increased risk of reactivation in patients who are chronic carriers. Some cases have been fatal. If reactivation occurs, stop HUMIRA and begin antiviral therapy Demyelinating disease Exacerbation or new onset of central and peripheral disease, including multiple sclerosis and Guillain-Barré syndrome, may occur. Exercise caution when considering HUMIRA for patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders Anakinra Increased risk of serious infections. Combination of HUMIRA and anakinra is not recommended. Live vaccines Should not be given to patients on HUMIRA. Hematological reactions Cytopenias, pancytopenia. Advise patients to seek immediate medical attention if symptoms develop, and consider stopping HUMIRA Heart failure Worsening or new-onset CHF may occur. Exercise caution when using HUMIRA in patients who have heart failure, and monitor them carefully Discontinuations due to adverse events were 7% for HUMIRA vs 4% for placebo Autoimmunity Development of autoantibodies and lupus-like syndrome. Stop HUMIRA if lupus-like syndrome develops In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn s disease, and plaque psoriasis the safety profile for patients treated with HUMIRA was similar to the safety profile seen in patients with rheumatoid arthritis

19 Chart styles and details MEAN CHANGE FROM BASELINE Extrapolated analysis a b P< HUMIRA 40 mg EOW + MTX (n=268) MTX (n=257) b 1.3 b 1.9 b WEEK 78 5X GREATER INHIBITION Legend: All Caps 8 pts Helvetica Neue 47 light Condensed Upper left corner Rule, tick grid, weight:.05 All Caps 9 pts Helvetica Neue 57 light Condensed center vertically All Caps 9 pts Helvetica Neue 57 light Condensed center Axes numbers 8 pts, Helvetica Neue 47 light Condensed All Caps 7 pts Helvetica Neue 47 light Condensed center Rule weight:. 01 point 7 pts Helvetica Neue 47 light Condensed 799 b,c patients YEAR HUMIRA 40 mg EOW a + MTX (n=268) Primary endpoints MTX weekly (n=257) HUMIRA 40 mg EOW (n=274) a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and corticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, as needed/as tolerated. The co-primary endpoints were ACR50 response and change in modified total Sharp score (mtss) at Year 1 for HUMIRA + MTX vs MTX alone. Helvetica Neue LT Std 67 Medium Condensed 9/10 pts Helvetica Neue LT Std 47 Light Condensed 7/8 pts 19

20 Chart styles and details (continued) All Caps 7 pts Helvetica Neue 77 Bold Condensed center NRI analysis a ACR ACR70 HUMIRA 40 mg EOW + MTX (n=268) MTX alone (n=257) b P< Legend: 7 pts Helvetica Neue 47 light Condensed Upper left corner PATIENTS (%) % b 46% 59% b % b 43% PATIENTS (%) 47% b % 28% 0 YEAR 1 YEAR 2 0 Rule weight:. YEAR 1 YEAR point 9 pts Helvetica Neue 57 light Condensed Numbers:8 pts Helvetica Neue 57 light Condensed HUMIRA + MTX (n=268) HUMIRA (n=274) MTX (n=257) Age (yrs) 51.9 ± ± ± 13.1 % female % with prior disease-modifying antirheumatic drugs (DMARDs) Table created in InDesign Alternating row color scheme C0/M30/Y100/K025 % and 30% % taking corticosteroids Years of RA 0.7 ± ± ± 0.9 SJC (0-66) 21.1 ± ± ± 11.7 TJC (0-68) 30.7 ± ± ± 14.3 C-reactive protein, mg/dl HAQ-DI DAS mtss b 18.1 ± ± ± 22.2 JE score b, 11.0 ± ± ± 13.6 Joint space narrowing (JSN) score b 7.1 ± ± ± 10.7 Estimated annual TSS progression Helvetica Neue 77 Bold Condensed 10 pts. HUMIRA PLUM Helvetica Neue LT Std 47 Light Condensed 9 pts a Unless otherwise indicated, results are mean ± SD. b n=267 in the HUMIRA + MTX group, 271 in the HUMIRA monotherapy group, and 251 in the MTX monotherapy group. c P<0.05 among treatment arms. Helvetica Neue LT Std 47 Light Condensed 7/6 pts 20

21 Slide Notes Layout Details PREMIER 2-Year Study Design Early Moderate to Severe RA SERIOUS INFECTIONS (continued) The risks and benefits of treatment with HUMIRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which HUMIRA is a member. a EOW=every other week. b Intent-to-treat population. c Stable doses of concomitant NSAIDs and c orticosteroids were permitted. Patients taking MTX escalated to 20 mg/wk by Week 8, asneeded/as tolerated. Breedveld FC et al. Arthritis Rheum. 2006;54: PREMIER 2-Year Study Design Patients 18 years old with a disease duration of <3 years were randomized to 1 of 3 treatment groups: HUMIRA 40 mg subcutaneously every other week plus weekly oral methotrexate (MTX) up to 20 mg/week; HUMIRA 40 mg subcutaneously every other week; or weekly oral MTX up to 20 mg/week. MTX was initiated at a dosage of 7.5 mg/week for the first 4 weeks. If the MTX was well tolerated and the patient continued to have any swollen or tender joints, the dosage could be escalated to 20 mg/week by week 8, as needed/as tolerated All patients received an injection (HUMIRA or placebo) and an oral medication (MTX or placebo) Study included a screening period, a 4-week washout period for patients taking other DMARDs and a 2-year, blinded-treatment period. safety area for text 799 MTX-naïve patients were enrolled in the study and 539 completed 2 years of treatment. Reference: Breedveld FC et al. Arthritis Rheum. 2006;54: Arial Bold 12 pts Flush left space after 12 points 12/14 Arial regular Black 6 points space before 12 points space after hanging 0.2 Reference Title: text: 11 points Arial Bold 11/12 pts Arial regulat Page numbers and Footer information optional per page 21

22 Global Specifications Safety area (pink dotted rule) x 6.7 (Nothing exceeds this area) Headlines start at edge of safety area, 24 points Arial Bold,Text box vertical alignment must be set to top single line leading, RGB=214, 0, 87,set internal margins to 0 Turn off auto fitting on a text boxes Bullets 115%, RGB = 214, 0, 87 Transitions setting on Slides -Wipe Up at Medium speed activated by click Body copy and Sub-bullets: Arial TT Regular 16 pts (Office Classic 2) Sub-bullets line spacing 0.2 points hanging, 0.6 points space before, 6 points space after Source copy/reference copy aligns with logo lock-up Flush left 8 points/10 leading 100% Black Page numbers: 8 points 100% black centered vertically and horizontally positioned on yellow bar Charts, Pictures, and Tables: Custom Animation animate as a wipe left, or right at medium speed; select: Start: After Previous Title slides Text: 36 points, 38 leading Flush left, Initial Caps, RGB = 214, 0, 87 Code number (XXX-XXXXX) 8 pts, white, bottom left edge (inside red graphic) aligns with page number Please see Abbott Representative for full Prescribing Information: 12 points, Arial Bold, Black, Flush left. Sits anchored bottom left edge. Text box is set to Bottom File must not exceed 10 MB- ideal size is 5 MB Output must be in 2 formats for PMR: Microsoft PowerPoint locked with password (Abbott01) to not allow changes. Printing, viewing, and forwarding is authorized. Adobe PDF (slideshow and speaker notes) for Macintosh users, locked with password (Abbott01) to not allow changes. Printing, viewing and forwarding is authorized. 22

påçííáëü=jéçáåáåéë=`çåëçêíáìã==

påçííáëü=jéçáåáåéë=`çåëçêíáìã== påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults

More information

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association

Immune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell

More information

You can find the PsA treatment support you want. You don t have to do this alone.

You can find the PsA treatment support you want. You don t have to do this alone. For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment

More information

You can find the PsA treatment support you want. You don t have to do this alone.

You can find the PsA treatment support you want. You don t have to do this alone. For adults with active Psoriatic arthritis (Ps a) There is a way forward. You can find the PsA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for the treatment

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment

More information

REMICADE (infliximab)

REMICADE (infliximab) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab)

More information

CIMZIA. Rheumatoid Arthritis

CIMZIA. Rheumatoid Arthritis PRESCRIBER Guide CIMZIA, in combination with methotrexate, is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying

More information

There is a way forward.

There is a way forward. For adults with moderate to severe Rheumatoid Arthritis (RA) There is a way forward. You can find the RA treatment support you want. You don t have to do this alone. Indication: CIMZIA is approved for

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HUMIRA - adalimumab injection, solution Abbott Laboratories ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively.

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment

More information

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced

More information

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010

subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP

More information

New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia

New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia June 12, 2015 New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of

More information

PRODUCT MONOGRAPH. HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection

PRODUCT MONOGRAPH. HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection PRODUCT MONOGRAPH Pr HUMIRA adalimumab 40 mg in 0.8 ml sterile solution (50 mg/ml) subcutaneous injection Biological Response Modifier HUMIRA (adalimumab) treatment should be initiated and supervised by

More information

-------------------------------CONTRAINDICATIONS------------------------------ Sepsis (4)

-------------------------------CONTRAINDICATIONS------------------------------ Sepsis (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel (etanercept) Solution

More information

What s new in clinical assesment of ankylosing spondylitis?

What s new in clinical assesment of ankylosing spondylitis? What s new in clinical assesment of ankylosing spondylitis? Désirée van der Heijde Professor of Rheumatology Leiden University Medical Center, the Netherlands Diakonhjemmet Hospital, Oslo, Norway Content

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

Medication Guide Enbrel (en-brel) (etanercept)

Medication Guide Enbrel (en-brel) (etanercept) Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide

More information

How To Treat A Tumor Necrosis Factor (Tnf) Blocker

How To Treat A Tumor Necrosis Factor (Tnf) Blocker HIGHLIGHTS OF PRESCRIBING INFORMA TION These highlights do not include all the information needed to use SIMPONI safely and effectively. See full prescribing information for SIMPONI. SIMPONI (golimumab)

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS

More information

Early identification and treatment - the Norwegian perspective. Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway

Early identification and treatment - the Norwegian perspective. Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway Early identification and treatment - the Norwegian perspective Till Uhlig Dept of Rheumatology Diakonhjemmet Hospital Oslo, Norway Oslo Rheumatoid Arthritis Registry (ORAR) Very early Arthritis Clinic

More information

Giant Spondylitis and Its Effect on Globlogical Therapy

Giant Spondylitis and Its Effect on Globlogical Therapy Cytokine and CAM Antagonists and Related Agents Review 01/22/2010 Copyright 2005-2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No

More information

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists

Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and

More information

Drug Therapy Guidelines: Humira (adalimumab)

Drug Therapy Guidelines: Humira (adalimumab) Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Recommendations for Early RA Patients

Recommendations for Early RA Patients SUPPLEMENTARY APPENDIX 5: Executive summary of recommendations for patients with early RA, established RA, and high-risk comorbidities Recommendations for Early RA Patients We strongly recommend using

More information

DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY

DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY ORIGINAL ARTICLES DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY Teodora Serban 1,2, Iulia Satulu 2, Oana Vutcanu 2, Mihaela Milicescu 1,2, Carina Mihai 1,2, Mihai Bojinca 1,2, Victor

More information

(CIM-zee-uh) HIGHLIGHTS OF PRESCRIBING INFORMATION WARNING: SERIOUS INFECTIONS AND MALIGNANCY

(CIM-zee-uh) HIGHLIGHTS OF PRESCRIBING INFORMATION WARNING: SERIOUS INFECTIONS AND MALIGNANCY (CIM-zee-uh) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CIMZIA safely and effectively. See full prescribing information for CIMZIA. CIMZIA (certolizumab

More information

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 14 December 2006 Doc. Ref. CHMP/EWP/438/04 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT

More information

Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015

Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Actemra (tocilizumab) Page 1 of 15 Origination Date: 09/14 Revision Date(s): 10/2015, 02/2016 Developed By: Medical Criteria Committee 10/28/2015

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,

More information

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Etanercept, infliximab and adalimumab for the treatment of Issued: August 2010 guidance.nice.org.uk/ta199 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis

Arthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,

More information

ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010

ACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)

More information

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. 2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically

More information

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the

More information

Standard of care for RA in SA 2013

Standard of care for RA in SA 2013 Standard of care for RA in SA 2013 Background Rheumatoid arthritis (RA) is a chronic inflammatory disease, which if treated inadequately leads to irreversible joint damage, resulting in deformities, disability

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must

More information

SECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products

SECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The

More information

ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA

ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA ath,, interrupt er p infusion es including ld ACTEMRA Lab Monitoring Guide 1 For DMARD-IR patients with moderate to severe RA eving an d laboratory n training and death, permanently s, platelets, d Indication

More information

ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections

ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections DATA SHEET ENBREL Etanercept (rch) NAME OF THE MEDICINE ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections ENBREL (Etanercept) 25 mg and 50 mg solution for injection in pre-filled

More information

Rheumatoid Arthritis: Constantly Evolving Treatment Approaches

Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Rheumatoid Arthritis: Constantly Evolving Treatment Approaches Jody Garry, Pharm.D. Primary Care Pharmacy Resident VA Medical Center - Iowa City Presentation Overview Pathophysiology & epidemiology Diagnostic

More information

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Patient Input Information Clinical Trials Outcomes Common Drug Review

Patient Input Information Clinical Trials Outcomes Common Drug Review CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted

More information

Understanding Rheumatoid Arthritis

Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result

More information

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified

Media Release. Basel, 11 June 2009. RA patients with enhanced response identified Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Issue date: August 2010

Issue date: August 2010 Issue date: August 2010 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Part review of NICE technology appraisal

More information

Evidence-based Management of Rheumatoid Arthritis (2009)

Evidence-based Management of Rheumatoid Arthritis (2009) CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance

More information

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?

Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept

More information

The Janssen Biotech Support System. Getting patients started on STELARA

The Janssen Biotech Support System. Getting patients started on STELARA The Janssen Biotech Support System Getting patients started on STELARA 3 STEPS after identifying patients appropriate for STELARA (ustekinumab) STEP 1: Determine the correct dose STELARA is administered

More information

Response to Public Comments From the Core Leadership Team for the ACR/SPARTAN/SAA Axial SpA Guideline Development Project July 2013

Response to Public Comments From the Core Leadership Team for the ACR/SPARTAN/SAA Axial SpA Guideline Development Project July 2013 We thank members of the rheumatology community for their interest in the proposed treatment recommendations for patients with axial spondyloarthritis (axspa) including ankylosing spondylitis (AS). In general,

More information

Rheumatoid Arthritis. Nicole Klett,, M.D.

Rheumatoid Arthritis. Nicole Klett,, M.D. Rheumatoid Arthritis Nicole Klett,, M.D. Rheumatoid Arthritis Systemic Chronic Inflammatory Primarily targets the synovium of diarthrodial joints Etiology likely combination genetic and environmental Diarthrodial

More information

How To Choose A Biologic Drug

How To Choose A Biologic Drug North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.

More information

Methotrexate Is Not Disease Modifying In Psoriatic Arthritis

Methotrexate Is Not Disease Modifying In Psoriatic Arthritis Methotrexate Is Not Disease Modifying In Psoriatic Arthritis A New Treatment Paradigm Is Required Gabrielle H Kingsley*, Jonathan Packham, Neil McHugh, Diarmuid Mulherin George Kitas, Kuntal Chakravarty,

More information

Dr Sarah Levy Consultant Rheumatology Croydon University Hospital

Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current

More information

Do I need a physician referral? Yes, we see patients on referral from a health care provider.

Do I need a physician referral? Yes, we see patients on referral from a health care provider. FAQS FOR OFFICE POLICIES How do I get an appointment? New appointments are made by physician referral only. Your referring health care provided will call for the appointment for you. What do I need to

More information

California SB 486 Needle Disposal Plan for SIMPONI (golimumab)

California SB 486 Needle Disposal Plan for SIMPONI (golimumab) California SB 486 Needle Disposal Plan for SIMPONI (golimumab) This describes the process in place for the end-of-life management of SIMPONI self-injection devices. SIMPONI (golimumab) is a drug for treatment

More information

ABOUT RHEUMATOID ARTHRITIS

ABOUT RHEUMATOID ARTHRITIS MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body

More information

How To Treat Ankylosing Spondylitis

How To Treat Ankylosing Spondylitis Inflammatory Arthritis and Biologic therapy Ministry of Health(MOH) Recommendations Biologic Therapy for Inflammatory Arthritis Ministry of Health Recommendations Introduction Chronic inflammatory arthropathies

More information

Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1

Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Morgan Schultz 1, Stephanie Keeling 2, Steven Katz 2, Walter Maksymowych 2, Dean Eurich 3, Jill Hall 1 1 Faculty of Pharmacy and Pharmaceutical Sciences, 2 Faciluty of Medicine and Dentistry, 3 School

More information

Cytokine and CAM Antagonists

Cytokine and CAM Antagonists Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs

More information

Rheumatoid Arthritis

Rheumatoid Arthritis Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly

More information

In the last decade, there have been major changes in the

In the last decade, there have been major changes in the 233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we

More information

Treatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR

Treatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: Enbrel Therapeutic Class: Miscellaneous Therapeutic Agents Therapeutic Sub-Class: Disease-modifying Antirheumatic Drugs Client: 2007 AARP Medicare Rx Inj, 2007

More information

1. Title 2. Background

1. Title 2. Background 1. Title EARLY PsA Effectiveness of early Adalimumab therapy in psoriatic arthritis patients from Reuma.pt, the Rheumatic Diseases Portuguese Register, Portuguese RheumatoLogy SocietY (SPR) 2. Background

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society

(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society Arthritis 101 (Intro to Arthritis with a Focus on Rheumatoid Arthritis) by Cari Taylor by Cari Taylor Manager of Education & Services for the Vancouver Island Region of The Arthritis Society What You Will

More information

Rheumatology Labs for Primary Care Providers. Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine

Rheumatology Labs for Primary Care Providers. Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine Rheumatology Labs for Primary Care Providers Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine Objectives Review the Indications for and Interpretation of lab testing for the following diseases:

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.

The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D. The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against

More information

NURS 821 Alterations in the Musculoskeletal System. Rheumatoid Arthritis. Type III Hypersensitivity Response

NURS 821 Alterations in the Musculoskeletal System. Rheumatoid Arthritis. Type III Hypersensitivity Response NURS 821 Alterations in the Musculoskeletal System Margaret H. Birney PhD, RN Lecture 12 Part 2 Joint Disorders (cont d) Rheumatoid Arthritis Definition: Autoimmune disorder occurring in genetically sensitive

More information

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before

More information

Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis

Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis 奇 美 醫 院 過 敏 免 疫 風 濕 科 陳 宏 安 Rheumatoid arthritis Most common chronic inflammatory joint disease Multisystem autoimmune disease of unknown

More information

Enbrel 25 mg powder and solvent for solution for injection.

Enbrel 25 mg powder and solvent for solution for injection. 1. NAME OF THE MEDICINAL PRODUCT Enbrel 25 mg powder and solvent for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 25 mg of etanercept. Etanercept is a human tumour

More information

Summary of the risk management plan (RMP) for Otezla (apremilast)

Summary of the risk management plan (RMP) for Otezla (apremilast) EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure

More information

Cytokine and CAM Antagonists

Cytokine and CAM Antagonists Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs

More information

Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago

Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease

More information

Guide To Creating Academic Posters Using Microsoft PowerPoint 2010

Guide To Creating Academic Posters Using Microsoft PowerPoint 2010 Guide To Creating Academic Posters Using Microsoft PowerPoint 2010 INFORMATION SERVICES Version 3.0 July 2011 Table of Contents Section 1 - Introduction... 1 Section 2 - Initial Preparation... 2 2.1 Overall

More information

Infl ectra for rheumatoid arthritis

Infl ectra for rheumatoid arthritis Infl ectra for rheumatoid arthritis Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction

More information

A New Era in Rheumatoid Arthritis Treatment

A New Era in Rheumatoid Arthritis Treatment A New Era in Rheumatoid Arthritis Treatment Jill C. Costello, MD; Paul B. Halverson, MD ABSTRACT Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily manifests as a chronic symmetric

More information

Rheumatoid Arthritis www.arthritis.org.nz

Rheumatoid Arthritis www.arthritis.org.nz Rheumatoid Arthritis www.arthritis.org.nz Did you know? RA is the second most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most often appears between

More information

Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis

Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis White Paper March 2013 Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis Catherine Augustyn, Brigham Walker, and Thomas F. Goss, PharmD Boston Healthcare Associates, Inc., Boston,

More information

CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments

CLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Medicines for Psoriatic Arthritis. A Review of the Research for Adults

Medicines for Psoriatic Arthritis. A Review of the Research for Adults Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy

Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy Improvement in Quality of Life of Rheumatoid Arthritis Patients on Biologic Therapy R Adams 1, Ct Ng 2, A Gibbs 2, L Tilson 1, D Veale 2, B Bresnihan 2, O FitzGerald 2, M Barry 1 1. National Centre for

More information

Rheumatoid Arthritis:

Rheumatoid Arthritis: Rheumatoid Arthritis Update 2014 Mark Hulsey, MD FACR Rheumatoid Arthritis Key Features Symptoms >6 weeks duration Often lasts the remainder of the patient s life Inflammatory synovitis Palpable synovial

More information

How To Take Methotrexate By Injection

How To Take Methotrexate By Injection How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate

More information

Can Rheumatoid Arthritis treatment ever be stopped?

Can Rheumatoid Arthritis treatment ever be stopped? Can Rheumatoid Arthritis treatment ever be stopped? Robert L. DiGiovanni, DO, FACOI Program Director Largo Medical Center Rheumatology Fellowship robdsimc@tampabay.rr.com Do not pour strange medicines

More information

Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine

Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Psoriasis is a chronic skin disorder resulting from a polygenic predisposition combined with

More information

A LTCI Approach to Managing Rheumatoid Arthritis

A LTCI Approach to Managing Rheumatoid Arthritis A LTCI Approach to Managing Rheumatoid Arthritis A bit of Science, a bit of Art, a lot of Perseverance... Stephen K. Holland, MD Senior Vice President & Medical Director Long Term Care Group, Inc. Long

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Remicade 100 mg powder for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains

More information

Rheumatoid Arthritis Information

Rheumatoid Arthritis Information Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative

More information